GSK's First China Scandal Of Summer May Have Been Result Of R&D Style
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline may have been the spark that ignited China's bribery crackdown in the pharma industry, but its first scandal was work on a multiple sclerosis drug, for which it was competing against Pfizer.